Latest action: Read twice and referred to the Committee on Finance.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Bill to improve security and safety of pharmaceutical supply chains in America.
The problem
Drug supply chains may be vulnerable to contamination, counterfeiting, or disruption. Protecting public health requires stronger oversight and security measures.
The proposal
Establishes security standards, tracking requirements, and oversight mechanisms for pharmaceutical manufacturing, distribution, and importation in the United States.
The impact
Affects drug makers, distributors, pharmacies, patients, and regulators. May increase drug safety but could raise costs and slow distribution.
Stronger security measures help prevent counterfeit drugs and contaminated medications from reaching patients. This reduces risks of serious harm or death from unsafe drugs.
Better tracking and oversight make it harder for criminals to introduce fake or dangerous drugs into the supply chain. Enhanced security deters illegal activity.
Patients gain assurance their medications are genuine and safe. Transparency in the supply chain builds trust in the pharmaceutical system.
Better supply chain monitoring helps identify and respond quickly to disruptions or threats during crises or natural disasters.
New security measures and tracking systems require investment by manufacturers and distributors. These costs may be passed to consumers through higher drug prices.
Additional security checks and compliance procedures could delay how quickly medications reach pharmacies and patients. Emergency situations might be affected.
Smaller pharmaceutical makers and distributors may struggle with costs of new security systems. Large companies with more resources could gain competitive advantage.
Creating new tracking systems across the entire supply chain is complex. Mistakes or delays in setup could create problems before benefits appear.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.